-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Net, March 12, the latest announcement of CSPC, 370 million yuan won two major varieties
Obtained exclusive authorization for blockbuster cancer drugs
On March 9, CSPC issued an announcement that CSPC (Shanghai) Co.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
According to the agreement, CSPC Shanghai will obtain the exclusive rights of BPI-7711 capsules to carry out commercialization activities of BPI-7711 capsules in the People’s Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding Taiwan) and own BPI -1178 Capsules (CDK4/6 inhibitor) commercialization authorization priority negotiation right.
At the same time, the group agreed to subscribe for equity from Beierda Pharmaceutical, with an initial subscription amount of RMB 200 million, which can only be implemented after certain prerequisites are fulfilled.
BPI-7711 is an irreversible and highly selective third-generation small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
According to Frost & Sullivan's data, it is estimated that by 2023, the market size of third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
It is understood that BPI-7711 capsules will soon submit a product marketing application in China.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
Re-obtained exclusive authorization for a new class of biological drug
On March 10th, CSPC announced again that Shanghai Jinmante Biotechnology Co.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
According to the agreement, Jinmante Bio will obtain the exclusive right of Connoa Bio to grant the product to the People’s Republic of China (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) for the product in these indications.
The development and commercialization of the company, and become the marketing authorization holder (MAH).
The development and commercialization of the company, and become the marketing authorization holder (MAH).
As an exclusive authorization, Jinmante Biotech agreed to pay a down payment of RMB 70 million to Connoa Bio and a development milestone payment of RMB 100 million based on the development progress of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
CM310 is an anti-IL-4Rα recombinant humanized monoclonal antibody injection with independent intellectual property rights developed by Connoa Biosciences.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
At present, the prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and allergic rhinitis remains high in China.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
Considering that CM310 has a broad patient base and reliable sales capabilities of CSPC, the sales prospect of CM310 is optimistic.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
However, due to the high-tech and high-risk characteristics of innovative pharmaceutical products, it is still necessary to pay attention to related risks.
Continue to increase the size of innovative drugs
CSPC has continued to increase its efforts in innovative drugs in recent years, and the batch harvest period of innovative drugs will usher in the next few years.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
On the one hand, it takes into account the company’s future development strategy, on the other hand, it also has the influence of the domestic policy environment and market trends.
After the “722” incident in 2015 and the 2016 new chemical drug classification reform, the approval of new clinical drugs has been further accelerated, gradually breaking the ice situation of domestic innovative drug research and development.
The number of domestic chemical innovative drugs IND is increasing year by year.
The number of domestic chemical innovative drugs IND is increasing year by year.
In October 2017, the Central Office of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices ", which involves accelerating the review and approval of marketing, promoting drug innovation and generic drug development, and improving technical support capabilities.
Reform opinions show that innovation is a long-term trend in the development of China's health care industry.
Reform opinions show that innovation is a long-term trend in the development of China's health care industry.
In addition, the medical reform represented by mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
In fact, my country's innovative drug market has huge potential.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
In short, innovative drugs are undoubtedly a market worth investing in.
Pharmaceutical Net, March 12, the latest announcement of CSPC, 370 million yuan won two major varieties
Obtained exclusive authorization for blockbuster cancer drugs
On March 9, CSPC issued an announcement that CSPC (Shanghai) Co.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
According to the agreement, CSPC Shanghai will obtain the exclusive rights of BPI-7711 capsules to carry out commercialization activities of BPI-7711 capsules in the People’s Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding Taiwan) and own BPI -1178 Capsules (CDK4/6 inhibitor) commercialization authorization priority negotiation right.
At the same time, the group agreed to subscribe for equity from Beierda Pharmaceutical, with an initial subscription amount of RMB 200 million, which can only be implemented after certain prerequisites are fulfilled.
BPI-7711 is an irreversible and highly selective third-generation small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
According to Frost & Sullivan's data, it is estimated that by 2023, the market size of third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
It is understood that BPI-7711 capsules will soon submit a product marketing application in China.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
Re-obtained exclusive authorization for a new class of biological drug
On March 10th, CSPC announced again that Shanghai Jinmante Biotechnology Co.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
According to the agreement, Jinmante Bio will obtain the exclusive right of Connoa Bio to grant the product to the People’s Republic of China (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) for the product in these indications.
The development and commercialization of the company, and become the marketing authorization holder (MAH).
The development and commercialization of the company, and become the marketing authorization holder (MAH).
As an exclusive authorization, Jinmante Biotech agreed to pay a down payment of RMB 70 million to Connoa Bio and a development milestone payment of RMB 100 million based on the development progress of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
CM310 is an anti-IL-4Rα recombinant humanized monoclonal antibody injection with independent intellectual property rights developed by Connoa Biosciences.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
At present, the prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and allergic rhinitis remains high in China.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
Considering that CM310 has a broad patient base and reliable sales capabilities of CSPC, the sales prospect of CM310 is optimistic.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
However, due to the high-tech and high-risk characteristics of innovative pharmaceutical products, it is still necessary to pay attention to related risks.
Continue to increase the size of innovative drugs
CSPC has continued to increase its efforts in innovative drugs in recent years, and the batch harvest period of innovative drugs will usher in the next few years.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
On the one hand, it takes into account the company’s future development strategy, on the other hand, it also has the influence of the domestic policy environment and market trends.
After the “722” incident in 2015 and the 2016 new chemical drug classification reform, the approval of new clinical drugs has been further accelerated, gradually breaking the ice situation of domestic innovative drug research and development.
The number of domestic chemical innovative drugs IND is increasing year by year.
The number of domestic chemical innovative drugs IND is increasing year by year.
In October 2017, the Central Office of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices ", which involves accelerating the review and approval of marketing, promoting drug innovation and generic drug development, and improving technical support capabilities.
Reform opinions show that innovation is a long-term trend in the development of China's health care industry.
Reform opinions show that innovation is a long-term trend in the development of China's health care industry.
In addition, the medical reform represented by mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
In fact, my country's innovative drug market has huge potential.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
In short, innovative drugs are undoubtedly a market worth investing in.
Pharmaceutical Net, March 12, the latest announcement of CSPC, 370 million yuan won two major varieties
Obtained exclusive authorization for blockbuster cancer drugs
Obtained exclusive authorization for blockbuster cancer drugs On March 9, CSPC issued an announcement that CSPC (Shanghai) Co.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
, Ltd.
, a wholly-owned subsidiary of the company, has entered into a product authorization and commercialization agreement with Shanghai Beierda Pharmaceutical Co.
, Ltd.
regarding its exclusive product BPI-7711 capsules.
Product licensing and commercialization.
According to the agreement, CSPC Shanghai will obtain the exclusive rights of BPI-7711 capsules to carry out commercialization activities of BPI-7711 capsules in the People’s Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding Taiwan) and own BPI -1178 Capsules (CDK4/6 inhibitor) commercialization authorization priority negotiation right.
At the same time, the group agreed to subscribe for equity from Beierda Pharmaceutical, with an initial subscription amount of RMB 200 million, which can only be implemented after certain prerequisites are fulfilled.
BPI-7711 is an irreversible and highly selective third-generation small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
Studies have shown that it has obvious anti- Tumor activity and better safety, judging from the published data, the efficacy and safety of the drug are similar to ametinib and osimertinib.
According to Frost & Sullivan's data, it is estimated that by 2023, the market size of third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
14 billion yuan to 10.
96 billion yuan.
The third-generation EGFR-TKI drugs currently on the market include AstraZeneca’s osimertinib, Hausen’s ametinib and Iris’ vometinib, which has recently been approved.
In addition, Essen’s Avitinib and the third-generation EGFR-TKI BPI-D0316 of Betta are likely to join the third-generation EGFR-TKI battlefield in the near future.
It is understood that BPI-7711 capsules will soon submit a product marketing application in China.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
CSPC stated that the introduction of this product will further enrich the group's oncology product line.
The Group's strong sales and promotion capabilities will accelerate the commercialization of this product and meet the urgent clinical needs of Chinese patients.
Re-obtained exclusive authorization for a new class of biological drug
Re-obtained exclusive authorization for a new class of biological drug On March 10th, CSPC announced again that Shanghai Jinmante Biotechnology Co.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
, Ltd.
, a wholly-owned subsidiary of the group, has entered into an agreement with Connoa Biomedical Technology (Chengdu) Co.
, Ltd.
, which relates to the product CM310 in moderate to severe asthma and chronic asthma.
Exclusive license development and commercialization of obstructive pulmonary disease (COPD) and other respiratory diseases.
According to the agreement, Jinmante Bio will obtain the exclusive right of Connoa Bio to grant the product to the People’s Republic of China (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) for the product in these indications.
The development and commercialization of the company, and become the marketing authorization holder (MAH).
The development and commercialization of the company, and become the marketing authorization holder (MAH).
As an exclusive authorization, Jinmante Biotech agreed to pay a down payment of RMB 70 million to Connoa Bio and a development milestone payment of RMB 100 million based on the development progress of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
Jinmante Biotech agreed to pay Connoa Biosciences milestone payments and sales commissions based on the sales of the product in the region.
CM310 is an anti-IL-4Rα recombinant humanized monoclonal antibody injection with independent intellectual property rights developed by Connoa Biosciences.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
It is intended to be used for the treatment of moderate to severe asthma, COPD and atopic dermatitis.
The product is declared as a Class 1 new drug for therapeutic biological products in China, and phase II clinical research has been carried out.
At present, the prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and allergic rhinitis remains high in China.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
The drug market in this field is considered to be one of the most promising markets in the future.
According to public data, the asthma market will reach 16.
1 billion US dollars in 2023.
Considering that CM310 has a broad patient base and reliable sales capabilities of CSPC, the sales prospect of CM310 is optimistic.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
In addition, the patented drug Dupixent will achieve global sales of 4 billion U.
S.
dollars in 2020, which also shows the commercial potential of CM310.
However, due to the high-tech and high-risk characteristics of innovative pharmaceutical products, it is still necessary to pay attention to related risks.
Continue to increase the size of innovative drugs
Continue to increase the size of innovative drugs CSPC has continued to increase its efforts in innovative drugs in recent years, and the batch harvest period of innovative drugs will usher in the next few years.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
According to estimates by brokerage firms, 3-5 new drug varieties are expected to be launched every year from 2020 to 2022.
In addition, it is also actively engaged in epitaxial mergers and acquisitions to obtain the development and commercialization rights of small molecule tumor drugs and monoclonal antibodies.
On the one hand, it takes into account the company’s future development strategy, on the other hand, it also has the influence of the domestic policy environment and market trends.
After the “722” incident in 2015 and the 2016 new chemical drug classification reform, the approval of new clinical drugs has been further accelerated, gradually breaking the ice situation of domestic innovative drug research and development.
The number of domestic chemical innovative drugs IND is increasing year by year.
The number of domestic chemical innovative drugs IND is increasing year by year.
In October 2017, the Central Office of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices ", which involves accelerating the review and approval of marketing, promoting drug innovation and generic drug development, and improving technical support capabilities.
Reform opinions show that innovation is a long-term trend in the development of China's health care industry.
Drugs medical equipment medicines medicines Medical Devices Medical DevicesReform opinions show that innovation is a long-term trend in the development of China's health care industry.
In addition, the medical reform represented by mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
pharmnet. com.
cn/news/yyzb/" target="_blank">procurement has accelerated the pace of price cuts for generic drugs and high-value consumables, and the profitability of generic drugs has fallen sharply.
It is imperative for domestic pharmaceutical companies to innovate.
The issuance of the new version of the drug registration management measures further requires the review time limit, and continues to support and encourage innovative research and development.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement pharmaceutical companies Pharmaceutical pharmaceutical business enterprises
In fact, my country's innovative drug market has huge potential.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
According to Minai data, the overall size of my country's drug terminal market in 2019 is about 2 trillion, of which innovative drugs account for only about 5%.
It is conservatively assumed that the overall drug market in my country will maintain a relatively low compound growth rate of about 4.
14% in the next 10 years, and then conservatively assume that the proportion of innovative drugs in my country will increase to about 33% (conservative estimation is lower than that of Europe, America and Japan) to a scale of 1 trillion.
Therefore, there is 10 times the space for my country's innovative drugs in 10 years.
In short, innovative drugs are undoubtedly a market worth investing in.
